Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047 | Synapse
September 10, 2025Open Access
Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047
Key Points
PFS was notably different between patients with low and medium LAG-3 tumors, indicating potential treatment variability.
Patients treated with NIVO plus RELA showed differing outcomes based on LAG-3/CD8+ tumor levels, suggesting biomarker utility.
Stratified analyses revealed insights into the different responses to immunotherapy in advanced melanoma patients, shaping future treatment routes.
Findings may support the incorporation of LAG-3 as a biomarker for patient stratification in advanced melanoma treatments.
Abstract
PFS stratified by low or medium LAG-3+/−CD8+ tumors in patients treated with NIVO + RELA compared with NIVO.